Acrux Ltd has released a press release.
FY24 Full Year Results - Investor Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Acrux
- Appendix 4E and FY24 Full Year Statutory Accounts
- FDA Approval received for Dapsone Gel, 7.5%
- Quarterly Activities Report and Appendix 4C - June 2024
- Acrux presentation to Bioshares, 18th Biotech Summit
- RDTI funding facility secured
Later from Acrux
- ASX Small and Mid Cap Conference presentation
- FY24 R&D Tax Incentive rebate received
- AGM Presentation
- Trading Halt
- FDA Approval - Nitroglycerin Ointment
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux